overabundance

WordNet

a quantity that is more than what is appropriate; "four-year-olds have an overabundance of energy"; "we received an inundation of email" (同)overmuch, overmuchness, superabundance

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/08/30 17:58:38」(JST)

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Rare copy number variants and congenital heart defects in the 22q11.2 deletion syndrome.

Mlynarski EE1, Xie M2, Taylor D2, Sheridan MB1, Guo T3, Racedo SE3, McDonald-McGinn DM1,4, Chow EW5, Vorstman J6, Swillen A7, Devriendt K7, Breckpot J7, Digilio MC8, Marino B9, Dallapiccola B8, Philip N10, Simon TJ11, Roberts AE12, Piotrowicz M13, Bearden CE14, Eliez S15, Gothelf D16,17, Coleman K18, Kates WR19, Devoto M1,4,20,21, Zackai E1,4, Heine-Suñer D22, Goldmuntz E4,23, Bassett AS5, Morrow BE3, Emanuel BS24,25; International Chromosome 22q11.2 Consortium.
Human genetics.Hum Genet.2016 Mar;135(3):273-85. doi: 10.1007/s00439-015-1623-9. Epub 2016 Jan 7.
The 22q11.2 deletion syndrome (22q11DS; velocardiofacial/DiGeorge syndrome; VCFS/DGS; MIM #192430; 188400) is the most common microdeletion syndrome. The phenotypic presentation of 22q11DS is highly variable; approximately 60-75 % of 22q11DS patients have been reported to have a congenital heart de
PMID 26742502

Hepatocyte growth factor-expressing adenovirus upregulates matrix metalloproteinase-1 expression in keloid fibroblasts.

Jeon YR1, Ahn HM2, Choi IK2, Yun CO2, Rah DK1, Lew DH1, Lee WJ1.
International journal of dermatology.Int J Dermatol.2016 Mar;55(3):356-61. doi: 10.1111/ijd.12965. Epub 2015 Jul 31.
BACKGROUND: Keloids are marked by an overabundance of extracellular matrix. The antifibrotic effect of hepatocyte growth factor (HGF) is achieved by increasing the expression of matrix metalloproteinases (MMPs) that drive extracellular matrix catabolism. As such, we cultivated an RGD-modified HGF-ex
PMID 26234705

Dutch-Flemish translation of nine pediatric item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS)(®).

Haverman L1, Grootenhuis MA2, Raat H3, van Rossum MA4,5, van Dulmen-den Broeder E6, Hoppenbrouwers K7, Correia H8, Cella D9, Roorda LD10, Terwee CB11.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.Qual Life Res.2016 Mar;25(3):761-5. doi: 10.1007/s11136-015-0966-y. Epub 2015 Mar 28.
PURPOSE: The Patient-Reported Outcomes Measurement Information System (PROMIS(®)) is a new, state-of-the-art assessment system for measuring patient-reported health and well-being of adults and children. It has the potential to be more valid, reliable, and responsive than existing PROMs. The items
PMID 25820548